7
www.epmmagazine.com
CRO
RECOGNISED FOR CONTRIBUTION TO WELSH ECONOMY
A
fast-growing contract research organisation (CRO) has been recognised for its contribution to the Welsh economy. CatSci was named ‘International Business of the Year’ at the Cardiff Business Awards, which recognises outstanding export performance in South Wales.
boration disease highly relevant novel drug targets. We are tremendously excited by the complementarity of our technologies. C4XD’s Conformetrix approach is ideally suited to use the 3D biological shape information derived from Siteseeker and convert this into small molecules starting points that will lead to the next generation of therapeutics.”
The company was also named as one of the ‘50 Most Exciting Companies in Wales’ by Wales Business Insider magazine. CatSci says that the awards reflect the longterm internationalisation strategy that is targeting key markets across the world. Simon Tyler, chief operating officer, said: “These accolades are a testament to the talent and hard work of all our staff. Both demonstrate CatSci’s growth into a globally-recognised partner for pharmaceutical innovation, and its commitment to life science in South Wales. We are proud to be an integral part of research and development efforts that lead to life-changing new therapeutics.”
CERTARA LAUNCHES GLOBAL SCHEME FOR DRUG DEVELOPMENT G
lobal drug development consultancy Certara has launched a new practice area to help accelerate medicines for people around the world who need them most. Certara Global Health will take an interdisciplinary approach to accelerating drug development across a range of areas. These include model-informed translational medicine; innovative clinical trial designs; regulatory science approaches to accelerate reviews and more. One area Certara Global Health will tackle is in delivering quality medicine to low-middle income countries through by bringing in new chemistry,
manufacturing and control (CMC) talent to tackle CMC challenges. Certara Global Health has been launched as a new product inspired by the company’s drug development and scientific work for the Bill & Melinda Gates Foundaiton. “Certara Global Health will bring together talent, technology, software, systems and processes to accelerate the development of medicines for those that need them most,” said Craig Rayner, co-lead of CGH. “Working closely with the foundation and other leaders in the global health sector, CGH will focus on creating novel and impactful drug development, regulatory science and patient
access approaches that will deliver effective and affordable therapies to populations in need around the world. A triple bottom line practice across the global health product development ecosystem.” “Developing medicines is expensive and difficult at the best of times, and securing talent and capital is an extra challenge for the global health sector,” added Kevin Hershberger, co-lead of CGH. “But we are confident that we can play a catalytic role in bringing creative thinkers together with leading-edge technologies and methodologies, to support solving medicine development and access challenges in global health.”